CSChaisith Sivakorn

Chaisith Sivakorn

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Chaisith Sivakorn has a total of 128 co-authors. Here are the top co-authors by number of shared publications:

  • Marcus Josephus Schultz

    Department of Anaesthesia, General Intensive Care and Pain Management, Division of Cardiothoracic and Vascular Anaesthesia & Critical Care Medicine, Medical University Wien, 1090 Vienna, Austria

    8 shared publications
  • Arjen Mattheus Dondorp

    Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand

    4 shared publications
  • Viravarn Luvira

    Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand

    4 shared publications
  • Arjen M. Dondorp

    Mahidol–Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine Mahidol University, Bangkok, Thailand

    3 shared publications
  • Luigi Pisani

    Department of Precision-Regenerative Medicine and Jonic Area, Section of Anesthesiology and Intensive Care Medicine, University of Bari "Aldo Moro" - Bari, Italy

    3 shared publications
  • Marcus J. Schultz

    Mahidol–Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine Mahidol University, Bangkok, Thailand

    3 shared publications

Latest Publications

  • Open Access

    Conservative Treatment of Spontaneous Intraperitoneal Hemorrhage in Severe Dengue: A Case Report and Review

    by Panita Looareesuwan, Chaisith Sivakorn, Viravarn Luvira

    : Dengue fever is a common arboviral illness that can result in severe hemorrhagic complications, although spontaneous intraperitoneal bleeding remains rare. We report the case of a 26-year-old previously healthy female who presented with a 4-day history of high-grade fever and myalgia that was later diagnosed as dengue fever. During hospitalization, she developed vaginal bleeding followed by generalized abdominal pain and shock. Contrast-enhanced computed tomography revealed significant hemoperitoneum, despite a normal coagulation profile and no identifiable bleeding source. She was managed conservatively with supportive care and made a full recovery. A 1-year follow-up was unremarkable. This case underscores the importance of early recognition, prompt imaging, and consideration of differential diagnoses. In the absence of established guidelines for managing spontaneous intraperitoneal hemorrhage in dengue, individualized conservative treatment may be effective. Clinicians should remain vigilant for atypical presentations to ensure timely diagnosis and appropriate management.

  • Open Access

    Effects of Different Bedside Physiotherapy Frequencies in Hospitalized COVID-19 Patients, Focusing on Mild to Moderate Cases

    by Netchanok Jianramas, Thanaporn Semphuet, Veeranoot Nissapatorn, Chaisith Sivakorn, Maria de Lourdes Pereira, Anuttra (Chaovavanich) Ratnarathon, Chenpak Salesingh, Eittipad Jaiyen, Salinee Chaiyakul, Nitita Piya-Amornphan, et al.

    Currently, knowledge of the effects of different frequencies of administration of bedside physiotherapy programs (PTPs) on hospitalized COVID-19 patients is limited. Therefore, this study aimed to compare the effects of administering PTPs once or twice during hospitalization versus daily PTPs until discharge. Fifty-two COVID-19 patients were equally assigned to two groups, matched by gender and age (1:1 ratio). Experimental Group 1 (Ex-G1) received PTPs one to two times during hospitalization, while Experimental Group 2 (Ex-G2) received daily PTPs until discharge. The outcomes assessed included the survival rate, length of hospitalization (LoH), intensive care unit (ICU) referrals, and in-hospital complications. Most participants were classified as having mild to moderate COVID-19, with a mean age of 45 years. No significant differences were observed between the groups in all primary outcomes, including the survival rate (p = 1.000), LoH (p = 0.117), ICU referrals (p = 0.313), and complications (p = 0.555). The overall survival rate was 98%. One Ex-G2 participant was referred to the ICU, while complications occurred in two Ex-G1 and four Ex-G2 participants. In summary, for patients with mild to moderate COVID-19, one to two bedside physiotherapy sessions produced comparable results to daily physiotherapy in terms of the survival rate, LoH, ICU referrals, and in-hospital complications.


  • Open Access

    Severity of COVID-19 in Patients with Diarrhoea: A Systematic Review and Meta-Analysis

    by Sunita Dhakal, Pimphen Charoen, Wirichada Pan-Ngum, Viravarn Luvira, Chaisith Sivakorn, Borimas Hanboonkunupakarn, Sakkarin Chirapongsathorn, Kittiyod Poovorawan

    COVID-19 patients occasionally present with diarrhoea. Our objective was to estimate the risk of developing the severe disease in COVID-19 patients with and without diarrhoea and to provide a more precise estimate of the prevalence of COVID-19-associated digestive symptoms. A total of 88 studies (n = 67,794) on patients with a COVID-19 infection published between 1 January 2020 and 20 October 2022 were included in this meta-analysis. The overall prevalence of digestive symptoms was 27% (95% confidence interval (CI): 21–34%; I2 = 99%). According to our data, the pooled prevalence of diarrhoea symptoms in the 88 studies analysed was 17% (95% CI: 14–20%; I2 = 98%). The pooled estimate of nausea or vomiting in a total of 60 studies was 12% (95% CI: 8–15%; I2 = 98%). We also analysed 23 studies with eligible individuals (n = 3800) to assess the association between the disease severity and diarrhoea. Individuals who had diarrhoea were more likely to have experienced severe COVID-19 (odds ratio: 1.71; 95% CI: 1.31–2.24; p < 0.0001; I2 = 10%). Gastrointestinal symptoms and diarrhoea are frequently presenting COVID-19 manifestations that physicians should be aware of.


  • Open Access

    The RALE Score Versus the CT Severity Score in Invasively Ventilated COVID-19 Patients—A Retrospective Study Comparing Their Prognostic Capacities

    by Christel M. Valk, Claudio Zimatore, Guido Mazzinari, Charalampos Pierrakos, Chaisith Sivakorn, Jutamas Dechsanga, Salvatore Grasso, Ludo Beenen, Lieuwe D. J. Bos, Frederique Paulus, et al.

    Background: Quantitative radiological scores for the extent and severity of pulmonary infiltrates based on chest radiography (CXR) and computed tomography (CT) scan are increasingly used in critically ill invasively ventilated patients. This study aimed to determine and compare the prognostic capacity of the Radiographic Assessment of Lung Edema (RALE) score and the chest CT Severity Score (CTSS) in a cohort of invasively ventilated patients with acute respiratory distress syndrome (ARDS) due to COVID-19. Methods: Two-center retrospective observational study, including consecutive invasively ventilated COVID-19 patients. Trained scorers calculated the RALE score of first available CXR and the CTSS of the first available CT scan. The primary outcome was ICU mortality; secondary outcomes were duration of ventilation in survivors, length of stay in ICU, and hospital-, 28-, and 90-day mortality. Prognostic accuracy for ICU death was expressed using odds ratios and Area Under the Receiver Operating Characteristic curves (AUROC). Results: A total of 82 patients were enrolled. The median RALE score (22 [15–37] vs. 26 [20–39]; p = 0.34) and the median CTSS (18 [16–21] vs. 21 [18–23]; p = 0.022) were both lower in ICU survivors compared to ICU non-survivors, although only the difference in CTSS reached statistical significance. While no association was observed between ICU mortality and RALE score (OR 1.35 [95%CI 0.64–2.84]; p = 0.417; AUC 0.50 [0.44–0.56], this was noticed with the CTSS (OR, 2.31 [1.22–4.38]; p = 0.010) although with poor prognostic capacity (AUC 0.64 [0.57–0.69]). The correlation between the RALE score and CTSS was weak (r2 = 0.075; p = 0.012). Conclusions: Despite poor prognostic capacity, only CTSS was associated with ICU mortality in our cohort of COVID-19 patients.


  • Open Access

    Efficacy and Safety of Immunomodulators in Patients with COVID-19: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials

    by Thundon Ngamprasertchai, Rattagan Kajeekul, Chaisith Sivakorn, Narisa Ruenroegnboon, Viravarn Luvira, Tanaya Siripoon, Nantasit Luangasanatip

    Introduction Many immunomodulators have been studied in clinical trials for the treatment of coronavirus disease 2019 (COVID-19). However, data identifying the most effective and safest treatment are lacking. We conducted a systematic review and network meta-analysis to rank immunomodulators in the treatment of COVID-19 according to their efficacy and safety. Methods Published and peer-reviewed randomized controlled trials assessing the efficacy of immunomodulators in hospitalized patients with COVID-19 were searched up to June 30, 2021. Direct and network meta-analyses were applied to assess the outcomes. The probability of efficacy and safety was estimated, and the drugs were awarded a numerical ranking. Results Twenty-six studies were eligible. Compared with standard of care, dexamethasone and tocilizumab had significantly lower mortality rates with pooled risk ratios (RRs) of 0.91 (95% confidence interval [CI] 0.84–0.99) and 0.88 (95% CI 0.82–0.96), respectively. Meanwhile, the most effective corticosteroid, interleukin-6 antagonist, and Janus kinase (JAK) inhibitor were hydrocortisone, sarilumab, and ruxolitinib, respectively. However, when superimposed infection was considered, ruxolitinib was the best treatment followed by baricitinib. Moreover, methylprednisolone had the worst combined efficacy and safety among the examined treatments. Conclusions Overall, immunomodulators were more effective than standard of care. Important differences exist among immunomodulators regarding both efficacy and safety in favor of ruxolitinib and baricitinib. Further well-conducted randomized controlled trials should focus on JAK inhibitors. Methylprednisolone use should be discouraged because of its poor efficacy and high risk of superimposed infection. Trial Registration PROSPERO registration identifier CRD 42021257421.


  • Open Access

    Dose-Dependent Blood-Feeding Activity and Ovarian Alterations to PM2.5 in Aedes aegypti

    by Thipruethai Phanitchat, Sumate Ampawong, Artit Yawootti, Thammanitchpol Denpetkul, Napid Wadmanee, Mongkhon Sompornrattanaphan, Chaisith Sivakorn

    High levels of fine particulate matter (PM2.5) air pollution are a concern for human health. Several studies have examined the effects of air pollution on human and animal health. However, there is a lack of knowledge about its effects on arbovirus vectors. Thus, we investigated whether PM2.5 concentration alters the blood-feeding activity of Ae. aegypti mosquitoes. We investigated the effect on the females’ propensity to blood feed at eight concentrations of PM2.5 ranging from 100 to 1000 μg/m3. Correlation analysis showed blood-feeding activity had a significant strong negative correlation with concentration of PM2.5 (rp = −0.85; p ≤ 0.00001). Exploratory linear and non-linear models showed an exponential decay relationship was the best fitting model (corrected Akaike’s information criterion, 193.0; Akaike’s weight, 0.766; adjusted R2, 0.780). Ultrastructural study demonstrated PM2.5 did not obstruct the respiratory system, but some fine particles were present on the antenna and abdominal body parts. Ovaries showed a dose–response relationship between PM2.5 level and vacuolated degeneration. In conclusion, the blood-feeding behavior of Ae. aegypti females may have an exponential decay relationship with PM2.5 level, and their ovaries may demonstrate dose-dependent degeneration. These findings may be important in understanding the vector’s biology and disease transmission in settings with high PM2.5 levels. These results are important to understand blood-feeding and feeding pattern of mosquitoes during PM2.5 pollution, which is important for disease transmission and vector control.


  • Open Access

    High Mobility Group Box 1 and Interleukin 6 at Intensive Care Unit Admission as Biomarkers in Critically Ill COVID-19 Patients

    by Chaisith Sivakorn, Jutamas Dechsanga, Lawan Jamjumrus, Kobporn Boonnak, Marcus J. Schultz, Arjen M. Dondorp, Weerapong Phumratanaprapin, Ranistha Ratanarat, Thummaporn Naorungroj, Patchrapa Wattanawinitchai, et al.

    : Exuberant inflammation manifesting as a “cytokine storm” has been suggested as a central feature in the pathogenesis of severe coronavirus disease 2019 (COVID-19). This study investigated two prognostic biomarkers, the high mobility group box 1 (HMGB1) and interleukin-6 (IL-6), in patients with severe COVID-19 at the time of admission in the intensive care unit (ICU). Of 60 ICU patients with COVID-19 enrolled and analyzed in this prospective cohort study, 48 patients (80%) were alive at ICU discharge. HMGB1 and IL-6 plasma levels at ICU admission were elevated compared with a healthy control, both in ICU nonsurvivors and ICU survivors. HMGB1 and IL-6 plasma levels were higher in patients with a higher Sequential Organ Failure Assessment (SOFA) score (> 10), and the presence of septic shock or acute kidney injury. HMGB1 and IL-6 plasma levels were also higher in patients with a poor oxygenation status (PaO2/FiO2 < 150 mm Hg) and a longer duration of ventilation (> 7 days). Plasma HMGB1 and IL-6 levels at ICU admission also correlated with other prognostic markers, including the maximum neutrophil/lymphocyte ratio, D-dimer levels, and C-reactive protein levels. Plasma HMGB1 and IL-6 levels at ICU admission predicted ICU mortality with comparable accuracy to the SOFA score and the COVID-GRAM risk score. Higher HMGB1 and IL-6 were not independently associated with ICU mortality after adjustment for age, gender, and comorbidities in multivariate analysis models. In conclusion, plasma HMGB1 and IL6 at ICU admission may serve as prognostic biomarkers in critically ill COVID-19 patients.


  • Open Access

    Awake Proning as an Adjunctive Therapy for Refractory Hypoxemia in Non-Intubated Patients with COVID-19 Acute Respiratory Failure: Guidance from an International Group of Healthcare Workers

    by Willemke Stilma, Eva Åkerman, Antonio Artigas, Andrew Bentley, Lieuwe D. Bos, Thomas J. C. Bosman, Hendrik de Bruin, Tobias Brummaier, Laura A. Buiteman-Kruizinga, Francesco Carcò, et al.

    Non-intubated patients with acute respiratory failure due to COVID-19 could benefit from awake proning. Awake proning is an attractive intervention in settings with limited resources, as it comes with no additional costs. However, awake proning remains poorly used probably because of unfamiliarity and uncertainties regarding potential benefits and practical application. To summarize evidence for benefit and to develop a set of pragmatic recommendations for awake proning in patients with COVID-19 pneumonia, focusing on settings where resources are limited, international healthcare professionals from high and low- and middle-income countries (LMICs) with known expertise in awake proning were invited to contribute expert advice. A growing number of observational studies describe the effects of awake proning in patients with COVID-19 pneumonia in whom hypoxemia is refractory to simple measures of supplementary oxygen. Awake proning improves oxygenation in most patients, usually within minutes, and reduces dyspnea and work of breathing. The effects are maintained for up to 1 hour after turning back to supine, and mostly disappear after 6–12 hours. In available studies, awake proning was not associated with a reduction in the rate of intubation for invasive ventilation. Awake proning comes with little complications if properly implemented and monitored. Pragmatic recommendations including indications and contraindications were formulated and adjusted for resource-limited settings. Awake proning, an adjunctive treatment for hypoxemia refractory to supplemental oxygen, seems safe in non-intubated patients with COVID-19 acute respiratory failure. We provide pragmatic recommendations including indications and contraindications for the use of awake proning in LMICs.


  • Open Access

    How to monitor cardiovascular function in critical illness in resource-limited settings

    by Chaisith Sivakorn, Marcus J. Schultz, Arjen M. Dondorp

    Purpose of review: Hemodynamic monitoring is an essential component in the care for critically ill patients. A range of tools are available and new approaches have been developed. This review summarizes their availability, affordability and feasibility for hospital settings in resource-limited settings. Recent findings: Evidence for the performance of specific hemodynamic monitoring tools or strategies in low-income and middle-income countries (LMICs) is limited. Repeated physical examination and basic observations remain a cornerstone for patient monitoring and have a high sensitivity for detecting organ hypoperfusion, but with a low specificity. Additional feasible approaches for hemodynamic monitoring in LMICs include: for tissue perfusion monitoring: urine output, skin mottling score, capillary refill time, skin temperature gradients, and blood lactate measurements; for cardiovascular monitoring: echocardiography and noninvasive or minimally invasive cardiac output measurements; and for fluid status monitoring: inferior vena cava distensibility index, mini-fluid challenge test, passive leg raising test, end-expiratory occlusion test and lung ultrasound. Tools with currently limited applicability in LMICs include microcirculatory monitoring devices and pulmonary artery catheterization, because of costs and limited added value. Especially ultrasound is a promising and affordable monitoring device for LMICs, and is increasingly available. Summary: A set of basic tools and approaches is available for adequate hemodynamic monitoring in resource-limited settings. Future research should focus on the development and trialing of robust and context-appropriate monitoring technologies.


  • Open Access

    Remote-Controlled and Pulse Pressure–Guided Fluid Treatment for Adult Patients with Viral Hemorrhagic Fevers

    by Marcus J. Schultz, Jacqueline Deen, Lorenz von Seidlein, Chaisith Sivakorn, Alex Kumar, Neill K. J. Adhikari, Bridget Wills, Alexander S. Kekulé, Nicholas P. J. Day, Ben Cooper, et al.

    Circulatory shock, caused by severe intravascular volume depletion resulting from gastrointestinal losses and profound capillary leak, is a common clinical feature of viral hemorrhagic fevers, including Ebola virus disease, Marburg hemorrhagic fever, and Lassa fever. These conditions are associated with high case fatality rates, and they carry a significant risk of infection for treating personnel. Optimized fluid therapy is the cornerstone of management of these diseases, but there are few data on the extent of fluid losses and the severity of the capillary leak in patients with VHFs, and no specific guidelines for fluid resuscitation and hemodynamic monitoring exist. We propose an innovative approach for monitoring VHF patients, in particular suited for low-resource settings, facilitating optimizing fluid therapy through remote-controlled and pulse pressure–guided fluid resuscitation. This strategy would increase the capacity for adequate supportive care, while decreasing the risk for virus transmission to health personnel.